文献速递神经免疫

多发性硬化患者结直肠癌生存率:一项匹配队列研究

Colorectal Cancer Survival in Multiple Sclerosis: A Matched Cohort Study.
PubMed 文献 · Neurology · 2021-10-04

该回顾性匹配队列研究基于加拿大曼尼托巴省和安大略省人群行政数据,比较多发性硬化(MS)与非MS结直肠癌患者的生存。纳入338例MS和1352例对照,按出生年、性别、诊断年、地区4:1匹配。调整后MS与诊断后6个月全因死亡风险增加相关(HR 1.45,95%CI 1.19-1.76),癌症特异性死亡风险仅在6个月时增加(HR 1.29,95%CI 1.04-1.61)。

要点

  • MS患者结直肠癌诊断后6个月全因死亡风险显著增加(HR 1.45)。
  • 癌症特异性死亡风险仅在6个月时增加(HR 1.29)。
  • 调整癌症分期后,MS仍与全因死亡(HR 1.60)和癌症特异性死亡(HR 1.47)风险增加相关。

核心结论

  • MS患者在结直肠癌诊断后早期(尤其是6个月)全因和癌症特异性生存率低于非MS患者。

研究设计与样本

  • 回顾性匹配队列研究,使用曼尼托巴省和安大略省行政数据,纳入338例MS和1352例非MS结直肠癌患者,按出生年、性别、癌症诊断年、地区4:1匹配。

主要发现

  • 调整后MS与全因死亡风险增加相关,6个月时HR 1.45(95%CI 1.19-1.76),1年HR 1.34(95%CI 1.09-1.63),2年HR 1.24(95%CI 0.99-1.56),5年HR 1.10(95%CI 0.80-1.50)。
  • MS与癌症特异性死亡风险增加仅在6个月时相关(HR 1.29,95%CI 1.04-1.61)。
  • 调整癌症分期后,MS与全因死亡(HR 1.60,95%CI 1.16-2.21)和癌症特异性死亡(HR 1.47,95%CI 1.02-2.12)风险增加相关。
  • 进一步调整残疾状态后,MS与全因死亡的关联部分减弱(HR 1.37,95%CI 0.97-1.92),与癌症特异性死亡的关联也部分减弱(HR 1.34,95%CI 0.91-1.97)。

临床怎么用

  • 对MS患者结直肠癌诊断后早期应加强监测和干预,以改善生存结局。

局限性

  • 研究为观察性设计,不能确定因果关系;残疾状态调整基于家庭护理或长期护理服务使用,可能不完全反映真实残疾程度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: We tested the hypothesis that overall and cancer-specific survival after a colorectal cancer diagnosis is lower in persons with multiple sclerosis (MS) than in those without MS using a retrospective matched cohort design. METHODS: Using population-based administrative data in Manitoba and Ontario, we identified persons with MS from a validated case definition and linked these cohorts to cancer registries to identify those with colorectal cancer. We selected persons with colorectal cancer and without MS, matching 4:1 on birth year, sex, cancer diagnosis year, and region. We used Cox proportional hazards regression to compare all-cause survival between cohorts, adjusting for age at cancer diagnosis, cancer diagnosis year, income, region, and Elixhauser comorbidity score. We compared cancer-specific survival between cohorts using a cause-specific hazards model. We pooled findings across provinces using random-effects meta-analysis. Complementary analyses using a subcohort from Ontario, adjusted for cancer stage and disability status, as measured from the use of home care or long-term care services. RESULTS: We included 338 MS cases and 1,352 controls with colorectal cancer. The mean (SD) age at cancer diagnosis was 64.7 (11.1) years. After adjustment, MS was associated with an increased hazard for all-cause death that was highest 6 months after diagnosis (hazard ratio [HR] 1.45, 95% confidence interval [CI] 1.19-1.76) and then declined over time (HR [95% CI] at 1 year 1.34 [1.09-1.63], 2 years 1.24 [0.99-1.56], 5 years 1.10 [0.80-1.50]). MS was associated with increased cancer-specific death at 6 months after diagnosis only (HR 1.29, 95% CI 1.04-1.61). After adjustment for cancer stage, MS was associated with an increased hazard of death due to any cause (1.60, 95% CI 1.16-2.21) and with cancer-specific death (HR 1.47, 95% CI 1.02-2.12). The association of MS and all-cause death was partially attenuated after adjustment for disability status (HR 1.37, 95% CI 0.97-1.92), as was the association with cancer-specific death (HR 1.34, 95% CI 0.91-1.97). DISCUSSION: Overall and cancer-specific survival was lower in persons with than without MS in the early period after colorectal cancer diagnosis. Further study is warranted to determine what factors underlie these worse outcomes.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Marrie RA, Maxwell C, Mahar A, et al. Colorectal Cancer Survival in Multiple Sclerosis: A Matched Cohort Study. Neurology. 2021. PMID: 34526374. doi:10.1212/WNL.0000000000012634

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。